



CME Session 2

Neuroimaging Committee

Sunday, October 5, 09:45 – 11:15

Session Title

Paradigm Shift for the Diagnosis of Parkinson's Disease

Chairpersons

Nelleke Toolbom (Utrecht, Netherlands)

Diego Cecchin (Padova, Italy)

Programme

- 09:45 – 10:05 **Cecilia Boccalini** (Geneva, Switzerland): FDG PET: not a physiopathological biomarker but ...
- 10:05 – 10:25 **Matteo Pardini** (Genova, Italy): DOPAMINERGIC IMAGING: a good old friend
- 10:25 – 10:45 **Valle Camacho** (Barcelona, Spain): MIBG: when, why ?
- 10:45 – 11:05 **Matthias Brendel** (Munich, Germany): NEW TRACERS UNDER DEVELOPMENT
- 11:05 – 11:15 Q&A

Educational Objectives

1. Learn about the current state-of-the-art imaging techniques in Parkinson's Disease.
2. Review of the role of FDG, MIBG, and dopaminergic imaging in the context of Parkinson's disease.
3. Understanding potential future biomarkers in Parkinson's disease.

Summary

In this CME session, the role of traditional tracers such as FDG, MIBG, and dopaminergic imaging in the context of Parkinson's disease will be explored. The potential future role of new biomarkers currently in advanced stages of development will also be discussed.

Key Words

MIBG; FDG; DAT IMAGING; DOPAMINERGIC IMAGING; MOVEMENT DISORDERS
BIOMARKERS